The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis

• Published in: Frontiers in cardiovascular medicine Vol. 9; p. 882089
• Main Authors: Lin, Yanxia, Zhang, Huanrui, Zhao, Shijie, Chen, Ling, Li, Jinyang, Wang, Xiaoou, Tian, Wen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 18.05.2022
• Subjects: angiotensin receptor-neprilysin inhibitor; Cardiovascular Medicine; combined therapy; heart failure; meta-analysis; sodium-glucose co-transporter-2 inhibitors; combined therapy; meta-analysis; heart failure; sodium-glucose co-transporter-2 inhibitors; angiotensin receptor-neprilysin inhibitor
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.882089

Both sodium-glucose co-transporter-2 (SGLT-2) inhibitors and angiotensin receptor-neprilysin inhibitor (ARNI) were recommended to treat heart failure with reduced ejection fraction (HFrEF). However, no trial was conducted to assess the efficacy and safety of the combined therapy of SGLT-2 inhibitors and ARNI in patients with HFrEF. We performed a meta-analysis of the prespecified subgroups from DAPA-HF and EMPEROR-Reduced trials. The primary endpoint was the composite risk of cardiovascular death or hospitalization for heart failure. The risk of cardiovascular death, all-cause death, a composite of serious adverse renal outcomes, and volume depletion were also estimated. The risk of the composite of cardiovascular death or hospitalization for heart failure was reduced in combined therapy of SGLT-2 inhibitors and ARNI, compared with ARNI monotherapy (RR.68, 95% CI.53 to.85, = 0.001). When compared with SGLT-2 inhibitors monotherapy, the events of cardiovascular death (RR.64, 95% CI.46 to 0.87, = 0.005) and all-cause death (RR.72, 95% CI.55 to.94, = 0.01) were significantly less in combined therapy, accompanied by elevated incidence of volume depletion (RR 1.55, 95% CI 1.22 to 1.96, = 0.0003). Combined therapy has additional benefits over monotherapy in patients with HFrEF, however, it is accompanied by a possibly higher risk of volume depletion.